GlaxoSmithKline (LON:GSK)‘s stock had its “equal weight” rating restated by equities researchers at Barclays Capital in a research report issued on Monday, StockRatingsNetwork.com reports. They currently have a GBX 1,610 ($25.56) price objective on the stock. Barclays Capital’s price objective indicates a potential downside of 0.74% from the stock’s previous close.
GlaxoSmithKline (LON:GSK) opened at 1630.50 on Monday. GlaxoSmithKline has a 52-week low of GBX 1194.5601 and a 52-week high of GBX 1816.00. The stock has a 50-day moving average of GBX 1664. and a 200-day moving average of GBX 1636.. The company’s market cap is £78.998 billion.
A number of other firms have also recently commented on GSK. Analysts at BNP Paribas reiterated an “underperform” rating on shares of GlaxoSmithKline (LON:GSK) in a research note to investors on Thursday. They now have a GBX 1,500 ($23.82) price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline (LON:GSK) in a research note to investors on Wednesday, September 11th. They now have a GBX 1,900 ($30.17) price target on the stock. Finally, analysts at Jefferies Group cut their price target on shares of GlaxoSmithKline (LON:GSK) from GBX 1,825 ($28.98) to GBX 1,800 ($28.58) in a research note to investors on Tuesday, September 10th. They now have a “hold” rating on the stock.
Five research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of GBX 1,644.93 ($26.12).
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.